LON:BMKBenchmark Share Price, Forecast & News

GBX 29

0.00 (0.00 %)

(As of 05/27/2020 06:07 AM ET)

Add

Compare

Today's Range

28.01

Now: GBX 29▼

29.50

50-Day Range

26.50

MA: GBX 31.75▼

34.50

52-Week Range

Now: GBX 29▼

56.90

Volume559,641 shs

Average Volume102,168 shs

Market Capitalization£193.61 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge for the development of food and farming industries worldwide. The company operates through Animal Health, Benchmark Genetics, Advanced Animal Nutrition, and All Other segments. The Animal Health segment provides veterinary and environmental diagnostics services, and animal health products to aquaculture, as well as manufactures licensed veterinary vaccines and components. The Benchmark Genetics segment offers salmon breeding technologies and production facilities to the harnesses industry to provide a range of genetic merit ova. The Advanced Animal Nutrition segment manufactures and offers nutrition and health products to the aquaculture industry. The All Other segment provides sustainable food production and technical consultancy, and assurance services; and promotes sustainable food production and ethics through online news and technical publications for the international agriculture and food processing sectors, as well as through delivery of training courses to industries. Benchmark Holdings plc was founded in 2000 and is headquartered in Sheffield, the United Kingdom.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Benchmark has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 92, Benchmark has a potential upside of 217.2% from its current price of GBX 29.
Amount of Analyst Coverage
Benchmark has received no research coverage in the past 90 days.

2.8 Community Rank

Outperform Votes
Benchmark has received 235 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Benchmark has received 179 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Benchmark has received 56.76% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Benchmark and other stocks. Vote “Outperform” if you believe BMK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Benchmark does not currently pay a dividend.
Dividend Growth
Benchmark does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Benchmark insiders have bought more of their company's stock than they have sold. Specifically, they have bought £5,070.76 in company stock and sold GBX 0 in company stock.

0.6 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Benchmark is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Benchmark is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Benchmark has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.99 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Manufacturers - Specialty & Generic

Sub-IndustryN/A

SectorMedical

Current SymbolLON:BMK

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.benchmarkplc.com

Phone+44-114-2409935

Debt

Debt-to-Equity Ratio38.68

Current Ratio2.40

Quick Ratio1.13

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales£122.75 million

Price / Sales1.58

Cash FlowGBX 3 per share

Price / Cash Flow9.67

Book ValueGBX 49 per share

Price / Book0.59

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares667,614,016

Market Cap£193.61 million

Next Earnings Date5/29/2020 (Estimated)

OptionableNot Optionable

Receive BMK News and Ratings via Email

Sign-up to receive the latest news and ratings for BMK and its competitors with MarketBeat's FREE daily newsletter.

Benchmark (LON:BMK) Frequently Asked Questions

How has Benchmark's stock been impacted by COVID-19 (Coronavirus)?

Benchmark's stock was trading at GBX 34.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BMK shares have decreased by 15.3% and is now trading at GBX 29. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Benchmark?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benchmark in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Benchmark.

When is Benchmark's next earnings date?

Benchmark is scheduled to release its next quarterly earnings announcement on Friday, May 29th 2020. View our earnings forecast for Benchmark.

What price target have analysts set for BMK?

1 brokers have issued 12-month price objectives for Benchmark's stock. Their forecasts range from GBX 92 to GBX 92. On average, they anticipate Benchmark's stock price to reach GBX 92 in the next twelve months. This suggests a possible upside of 217.2% from the stock's current price. View analysts' price targets for Benchmark.

Has Benchmark been receiving favorable news coverage?

Media stories about BMK stock have trended extremely positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Benchmark earned a media sentiment score of 5.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutBenchmark.

Who are some of Benchmark's key competitors?

Some companies that are related to Benchmark include HLS Therapeutics (HLS), OrganiGram (OGI), Hexo (HEXO), Next Science (NXS), ICC Labs (ICC), HEXO (HEXO), Amryt Pharma (AMYT), Green Organic Dutchman (TGOD), WeedMD (WMD), Probiotec (PBP), ESSA Pharma (EPI), CannTrust (TRST), Shield Therapeutics (STX), Supreme Cannabis (FIRE) and Althea Group (AGH). View all competitors.

What other stocks do shareholders of Benchmark own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benchmark investors own include Indivior (INDV), Allena Pharmaceuticals (ALNA), Redt Energy (RED), Ampliphi Biosciences (APHB), Clinigen Group (CLIN), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), American Campus Communities (ACC), AcelRx Pharmaceuticals (ACRX) and Aldeyra Therapeutics (ALDX).

Who are Benchmark's key executives?

Benchmark's management team includes the following people:

Mr. Malcolm David Foster Pye, CEO & Exec. Director (Age 62)
Mr. Mark James Plampin, CFO & Exec. Director (Age 51)
Ms. Ruth Layton, Co-Founder & Head of Benchmark Sustainability Science
Dr. Alexander Josef Raeber, Chief Scientific Officer & Exec. Director (Age 58)
Ms. Ivonne Cantu, Director of Investor Relations Director & Corp. Devel.

What is Benchmark's stock symbol?

Benchmark trades on the London Stock Exchange (LON) under the ticker symbol "BMK."

How do I buy shares of Benchmark?

Shares of BMK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Benchmark's stock price today?

One share of BMK stock can currently be purchased for approximately GBX 29.

How big of a company is Benchmark?

Benchmark has a market capitalization of £193.61 million and generates £122.75 million in revenue each year.

What is Benchmark's official website?

The official website for Benchmark is www.benchmarkplc.com.

How can I contact Benchmark?

Benchmark's mailing address is Benchmark House, 8 Smithy Wood Drive, SHEFFIELD, S35 1QN, United Kingdom. The company can be reached via phone at +44-114-2409935.

This page was last updated on 5/27/2020 by MarketBeat.com Staff